Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03831334 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
A Early Phase 1 study of Permanent Chemotherapy-induced Alopecia, sponsored by Northwestern University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03831334: Active Early Phase 1 study of Permanent Chemotherapy-induced Alopecia, sponsored by Northwestern University.
NCT03831334 is a Early Phase 1 study of Permanent Chemotherapy-induced Alopecia that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03831334, a Early Phase 1 study of Permanent Chemotherapy-induced Alopecia, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
An open label, pilot study involving the use of low dose oral minoxidil to treat permanent chemotherapy-induced alopecia.
Primary Outcome
Evaluation will be performed by the investigators at each visit (every 12 weeks) as measured by the Investigator Photographic Assessment Questionnaire (IPAQ)
Conditions Studied
Interventions
- DRUG oral minoxidil
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-04-09 |
| Est. Completion | 2025-08 |
| Phase | Early Phase 1 |
What the registry record for NCT03831334 still lists
NCT03831334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Permanent Chemotherapy-induced Alopecia appearing as the primary indexed condition, and to 1 intervention - of which oral minoxidil is the first listed.
NCT03831334 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03831334 about?
NCT03831334 is a clinical study titled "Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia". An open label, pilot study involving the use of low dose oral minoxidil to treat permanent chemotherapy-induced alopecia.
What is the current status of trial NCT03831334?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2019-04-09. Estimated completion is 2025-08.
What conditions does trial NCT03831334 study?
This clinical trial studies the following conditions: Permanent Chemotherapy-induced Alopecia.
What interventions are being tested in trial NCT03831334?
The interventions under investigation include: oral minoxidil (DRUG).
Who is sponsoring clinical trial NCT03831334?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03831334 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03831334's enrollment target sits among peer trials
14 1475th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy